FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028426028> ?p ?o ?g. }

• W2028426028 abstract "Abstract Background Aberrant ErbB receptor signaling is associated with various types of malignancies. γ-Tocotrienol is a member of the vitamin E family of compounds that displays potent anticancer activity that is associated with suppression in ErbB receptor phosphorylation and mitogenic signaling. Erlotinib and gefitinib are tyrosine kinase inhibitors that block ErbB1 receptor activation, whereas trastuzumab is a monoclonal antibody that has been designed to specifically inhibit ErbB2 receptor activation. However, the clinical effectiveness of these agents have been disappointing because of cooperation between different ErbB family members that can rescue cancer cells from agents directed against a single ErbB receptor subtype. It was hypothesized that targeting multiple ErbB receptor subtypes with combined treatment of γ-tocotrienol and ErbB receptor inhibitors would provide greater anticancer effects than monotherapy targeting only a single ErbB receptor subtype. Methods Highly malignant mouse +SA mammary epithelial cells were maintained in culture on serum-free defined media containing 10 ng/ml EGF as a mitogen. Cell viability wase determined by MTT assay, whereas Western blot and immunofluorescent staining was used to determine treatment effects on ErbB receptor subtype level and activation. Treatment-induced apoptosis was determined using annexin V staining and Western blot analysis of cleaved caspase-3 and PARP levels. Results Treatment with 3.5 μM γ-tocotrienol, 0.5 μM erlotinib or 1.0 μM gefitinib alone, significantly inhibited +SA tumor cell growth. Combined treatment with subeffective doses of erlotinib (0.25 μM) or gefitinib (0.5 μM) with subeffective doses of γ-tocotrienol (0.5-3.0 μM) significantly inhibited the growth and induced apoptosis in a dose-responsive manner. Trastuzumab treatment alone or in combination had no effect on +SA cell growth and viability. Combined treatment of γ-tocotrienol with erlotinib or gefitinib also cause a large decrease in ErbB3, ErbB4, and to a lesser extent ErbB2 receptor levels, and EGF-dependent ErbB2-4 tyrosine phosphorylation (activation), but had no effect on ErbB1 receptor levels or activation. Conclusion Combination treatment of γ-tocotrienol with specific ErbB receptor inhibitors is more effective in reducing mammary tumor cell growth and viability than high dose monotherapy, suggesting that targeting multiple ErbB receptors with combination therapy may significantly improve the therapeutic response in breast cancer patients." @default.
• W2028426028 created "2016-06-24" @default.
• W2028426028 creator A5027136080 @default.
• W2028426028 creator A5061101570 @default.
• W2028426028 creator A5089706720 @default.
• W2028426028 date "2010-03-08" @default.
• W2028426028 modified "2023-09-27" @default.
• W2028426028 title "Enhanced antiproliferative and apoptotic response to combined treatment of γ-tocotrienol with erlotinib or gefitinib in mammary tumor cells" @default.
• W2028426028 cites W1494555291 @default.
• W2028426028 cites W1523167405 @default.
• W2028426028 cites W1583830196 @default.
• W2028426028 cites W1601571585 @default.
• W2028426028 cites W1763666518 @default.
• W2028426028 cites W1782490506 @default.
• W2028426028 cites W1797430954 @default.
• W2028426028 cites W1964321121 @default.
• W2028426028 cites W1965309927 @default.
• W2028426028 cites W1970668232 @default.
• W2028426028 cites W1981108516 @default.
• W2028426028 cites W2006257247 @default.
• W2028426028 cites W2009218955 @default.
• W2028426028 cites W2010536491 @default.
• W2028426028 cites W2016440321 @default.
• W2028426028 cites W2017081079 @default.
• W2028426028 cites W2018289835 @default.
• W2028426028 cites W2022047264 @default.
• W2028426028 cites W2025561101 @default.
• W2028426028 cites W2028629615 @default.
• W2028426028 cites W2036752075 @default.
• W2028426028 cites W2051782283 @default.
• W2028426028 cites W2061448159 @default.
• W2028426028 cites W2069526613 @default.
• W2028426028 cites W2070638683 @default.
• W2028426028 cites W2079962331 @default.
• W2028426028 cites W2086358274 @default.
• W2028426028 cites W2090855460 @default.
• W2028426028 cites W2093889971 @default.
• W2028426028 cites W2100183121 @default.
• W2028426028 cites W2101108802 @default.
• W2028426028 cites W2102088611 @default.
• W2028426028 cites W2108398493 @default.
• W2028426028 cites W2108578140 @default.
• W2028426028 cites W2113013123 @default.
• W2028426028 cites W2123206362 @default.
• W2028426028 cites W2127806881 @default.
• W2028426028 cites W2130840817 @default.
• W2028426028 cites W2147304472 @default.
• W2028426028 cites W2159536158 @default.
• W2028426028 cites W2167341806 @default.
• W2028426028 cites W2182962878 @default.
• W2028426028 cites W2323068097 @default.
• W2028426028 cites W2329126676 @default.
• W2028426028 cites W4237043820 @default.
• W2028426028 cites W4376477728 @default.
• W2028426028 doi "https://doi.org/10.1186/1471-2407-10-84" @default.
• W2028426028 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2841143" @default.
• W2028426028 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20211018" @default.
• W2028426028 hasPublicationYear "2010" @default.
• W2028426028 type Work @default.
• W2028426028 sameAs 2028426028 @default.
• W2028426028 citedByCount "51" @default.
• W2028426028 countsByYear W20284260282012 @default.
• W2028426028 countsByYear W20284260282013 @default.
• W2028426028 countsByYear W20284260282014 @default.
• W2028426028 countsByYear W20284260282015 @default.
• W2028426028 countsByYear W20284260282016 @default.
• W2028426028 countsByYear W20284260282017 @default.
• W2028426028 countsByYear W20284260282018 @default.
• W2028426028 countsByYear W20284260282019 @default.
• W2028426028 countsByYear W20284260282020 @default.
• W2028426028 countsByYear W20284260282021 @default.
• W2028426028 countsByYear W20284260282023 @default.
• W2028426028 crossrefType "journal-article" @default.
• W2028426028 hasAuthorship W2028426028A5027136080 @default.
• W2028426028 hasAuthorship W2028426028A5061101570 @default.
• W2028426028 hasAuthorship W2028426028A5089706720 @default.
• W2028426028 hasBestOaLocation W20284260281 @default.
• W2028426028 hasConcept C126322002 @default.
• W2028426028 hasConcept C170493617 @default.
• W2028426028 hasConcept C2778087573 @default.
• W2028426028 hasConcept C2779251935 @default.
• W2028426028 hasConcept C2779438470 @default.
• W2028426028 hasConcept C2780580887 @default.
• W2028426028 hasConcept C502942594 @default.
• W2028426028 hasConcept C71924100 @default.
• W2028426028 hasConcept C98274493 @default.
• W2028426028 hasConceptScore W2028426028C126322002 @default.
• W2028426028 hasConceptScore W2028426028C170493617 @default.
• W2028426028 hasConceptScore W2028426028C2778087573 @default.
• W2028426028 hasConceptScore W2028426028C2779251935 @default.
• W2028426028 hasConceptScore W2028426028C2779438470 @default.
• W2028426028 hasConceptScore W2028426028C2780580887 @default.
• W2028426028 hasConceptScore W2028426028C502942594 @default.
• W2028426028 hasConceptScore W2028426028C71924100 @default.
• W2028426028 hasConceptScore W2028426028C98274493 @default.
• W2028426028 hasIssue "1" @default.
• W2028426028 hasLocation W20284260281 @default.
• W2028426028 hasLocation W20284260282 @default.
• W2028426028 hasLocation W20284260283 @default.
• W2028426028 hasLocation W20284260284 @default.

• next